ResMed Launches Home Sleep Apnea Test Across US; Shares Fall 3%
MT Newswires Live
04-04
ResMed (RMD:AX) launched its US Food and Drug Administration-cleared home sleep apnea test, NightOwl, across the US, according to a Friday statement by the company.
The fingertip sensor allows individuals to test for obstructive sleep apnea at home, the statement said.
Shares of the company fell nearly 3% in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
沒有相關數據